Skip to main content

Articles

Page 1 of 28

  1. Authors: Ignacio Illán-Gala, Victor Montal, Sergi Borrego-Écija, Maria Luisa Mandelli, Neus Falgàs, Ariane E. Welch, Jordi Pegueroles, Miguel Santos-Santos, Alexandre Bejanin, Daniel Alcolea, Oriol Dols-Icardo, Olivia Belbin, Mª. Belén Sánchez-Saudinós, Nuria Bargalló, Sofía González-Ortiz, Albert Lladó…
    Citation: Alzheimer's Research & Therapy 2023 15:29

    The original article was published in Alzheimer's Research & Therapy 2022 14:27

  2. Mild cognitive impairment (MCI) has been thought of as the transitional stage between normal ageing and Alzheimer’s disease, involving substantial changes in brain grey matter structures. As most previous stud...

    Authors: Mingxi Dang, Caishui Yang, Kewei Chen, Peng Lu, He Li and Zhanjun Zhang
    Citation: Alzheimer's Research & Therapy 2023 15:27
  3. To evaluate the potential of cerebrospinal fluid (CSF) levels of matrix metalloproteinases and tissue-type inhibitors (MMP; TIMP), and ratios of MMPs to TIMPs, to function as biomarkers for sporadic or heredit...

    Authors: Marc Vervuurt, Anna M. de Kort, Lieke Jäkel, Iris Kersten, Wilson F. Abdo, Floris H. B. M. Schreuder, Ingeborg Rasing, Gisela M. Terwindt, Marieke J. H. Wermer, Steven M. Greenberg, Catharina J. M. Klijn, H. Bea Kuiperij and Marcel M. Verbeek
    Citation: Alzheimer's Research & Therapy 2023 15:26
  4. Alzheimer’s disease (AD) is a complex and heterogeneous disease, which requires reliable biomarkers for diagnosis and monitoring disease activity. Preanalytical protocol and technical variability associated wi...

    Authors: Sterling C. Johnson, Marc Suárez-Calvet, Ivonne Suridjan, Carolina Minguillón, Juan Domingo Gispert, Erin Jonaitis, Agata Michna, Margherita Carboni, Tobias Bittner, Christina Rabe, Gwendlyn Kollmorgen, Henrik Zetterberg and Kaj Blennow
    Citation: Alzheimer's Research & Therapy 2023 15:25
  5. This phase II proof-of-concept study assessed the efficacy and safety of BI 425809, a novel selective glycine transporter-1 inhibitor, for the treatment of cognitive impairment associated with probable Alzheim...

    Authors: Glen Wunderlich, Zuzana Blahova, Miguel Garcia and Frank Jessen
    Citation: Alzheimer's Research & Therapy 2023 15:24
  6. Alzheimer’s disease (AD) is an incurable neurodegenerative disorder characterised by the progressive buildup of toxic amyloid-beta (Aβ) and tau protein aggregates eventually leading to cognitive decline. Recen...

    Authors: Inès R. H. Ben-Nejma, Aneta J. Keliris, Verdi Vanreusel, Peter Ponsaerts, Annemie Van der Linden and Georgios A. Keliris
    Citation: Alzheimer's Research & Therapy 2023 15:23
  7. Wide evidence suggests that physical activity (PA) confers protection against Alzheimer’s disease (AD). On the other hand, the apolipoprotein E gene (APOE) ε4 allele represents the greatest genetic risk factor fo...

    Authors: Jaisalmer de Frutos Lucas, Kelsey R. Sewell, Alejandra García-Colomo, Shaun Markovic, Kirk I. Erickson and Belinda M. Brown
    Citation: Alzheimer's Research & Therapy 2023 15:22
  8. Dementia [i.e., Alzheimer disease (AD)], the most common neurodegenerative disease, causes profound negative impacts on executive function and quality of life. Available pharmacological treatments often fail t...

    Authors: Ping-Tao Tseng, Yen-Wen Chen, Bing-Yan Zeng, Bing-Syuan Zeng, Chao-Ming Hung, Cheuk-Kwan Sun, Yu-Shian Cheng, Brendon Stubbs, Andre F. Carvalho, Andre R. Brunoni, Kuan-Pin Su, Yu-Kang Tu, Yi-Cheng Wu, Tien-Yu Chen, Pao-Yen Lin, Chih-Sung Liang…
    Citation: Alzheimer's Research & Therapy 2023 15:20
  9. The earliest pathological features of Alzheimer’s disease (AD) appear decades before the clinical symptoms. The pathology affects the brain and the eye, leading to retinal structural changes and functional vis...

    Authors: Inés López-Cuenca, Alberto Nebreda, Alejandra García-Colomo, Elena Salobrar-García, Jaisalmer de Frutos-Lucas, Ricardo Bruña, Ana I. Ramírez, Federico Ramirez-Toraño, Juan J. Salazar, Ana Barabash, Pedro Gil, Fernando Maestú, José M. Ramírez and Rosa de Hoz
    Citation: Alzheimer's Research & Therapy 2023 15:19
  10. Neuroinflammatory factors, especially chemokines, have been widely reported to be involved in the pathogenesis of Alzheimer’s disease (AD). It is unclear how chemokines are altered in AD, and whether dysregula...

    Authors: Xiao Li, Deng-Feng Zhang, Rui Bi, Li-Wen Tan, Xiaogang Chen, Min Xu and Yong-Gang Yao
    Citation: Alzheimer's Research & Therapy 2023 15:17
  11. Hyperphosphorylation and intraneuronal aggregation of the microtubule-associated protein tau is a major pathological hallmark of Alzheimer’s disease (AD) brain. Of special interest is the effect of cerebral am...

    Authors: Susan Barendrecht, An Schreurs, Stefanie Geissler, Victor Sabanov, Victoria Ilse, Vera Rieckmann, Rico Eichentopf, Anja Künemund, Benjamin Hietel, Sebastian Wussow, Katrin Hoffmann, Kerstin Körber-Ferl, Ravi Pandey, Gregory W. Carter, Hans-Ulrich Demuth, Max Holzer…
    Citation: Alzheimer's Research & Therapy 2023 15:16
  12. Atrial fibrillation (AF) is a strong risk factor for Alzheimer’s disease (AD) independent of ischemic stroke. However, the clinicopathological impact of AF on the severity of AD has not been well elucidated. W...

    Authors: Taizen Nakase, Yasuko Tatewaki, Benjamin Thyreau, Hayato Odagiri, Naoki Tomita, Shuzo Yamamoto, Yumi Takano, Michiho Muranaka and Yasuyuki Taki
    Citation: Alzheimer's Research & Therapy 2023 15:15
  13. Neuroinflammation constitutes a pathological hallmark of Alzheimer’s disease (AD). Still, it remains unresolved if peripheral inflammatory markers can be utilized for research purposes similar to blood-based b...

    Authors: Frederic Brosseron, Anne Maass, Luca Kleineidam, Kishore Aravind Ravichandran, Carl-Christian Kolbe, Steffen Wolfsgruber, Francesco Santarelli, Lisa M. Häsler, Róisín McManus, Christina Ising, Sandra Röske, Oliver Peters, Nicoleta-Carmen Cosma, Luisa-Sophie Schneider, Xiao Wang, Josef Priller…
    Citation: Alzheimer's Research & Therapy 2023 15:13
  14. Increasing physical activity is one of the most promising and challenging interventions to delay or prevent cognitive decline and dementia.

    Authors: Sara A. Galle, Jan Berend Deijen, Maarten V. Milders, Mathieu H. G. De Greef, Erik J. A. Scherder, Cornelia M. van Duijn and Madeleine L. Drent
    Citation: Alzheimer's Research & Therapy 2023 15:12
  15. Left-predominant neurodegeneration of the anterior temporal lobe (ATL) and the associated syndrome termed semantic variant primary progressive aphasia (svPPA) are well characterized. Less is known about right-...

    Authors: Lars Frings, Ganna Blazhenets, Raphael Binder, Tobias Bormann, Sabine Hellwig and Philipp T. Meyer
    Citation: Alzheimer's Research & Therapy 2023 15:11
  16. The risk of dementia is higher in women than men. The metabolic consequences of estrogen decline during menopause accelerate neuropathology in women. The use of hormone replacement therapy (HRT) in the prevent...

    Authors: Rasha N. M. Saleh, Michael Hornberger, Craig W. Ritchie and Anne Marie Minihane
    Citation: Alzheimer's Research & Therapy 2023 15:10
  17. The independent and additive associations of walking pace and grip strength on dementia risk and the potential modifying effects of age, APOE phenotypes, and other dementia risk factors on the walking pace and...

    Authors: Panpan He, Chun Zhou, Ziliang Ye, Mengyi Liu, Yuanyuan Zhang, Qimeng Wu, Yanjun Zhang, Sisi Yang, Gan Xiaoqin and Xianhui Qin
    Citation: Alzheimer's Research & Therapy 2023 15:9
  18. Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that is characterized by altered cellular metabolism in the brain. Several of these alterations have been found to be exacerbated in females...

    Authors: Abigail Strefeler, Maxime Jan, Manfredo Quadroni, Tony Teav, Nadia Rosenberg, Jean-Yves Chatton, Nicolas Guex, Hector Gallart-Ayala and Julijana Ivanisevic
    Citation: Alzheimer's Research & Therapy 2023 15:8
  19. Little is known regarding whether sex assigned at birth modifies the association between several predictive factors for dementia and the risk of dementia itself.

    Authors: Xianwen Shang, Eddy Roccati, Zhuoting Zhu, Katerina Kiburg, Wei Wang, Yu Huang, Xueli Zhang, Xiayin Zhang, Jiahao Liu, Shulin Tang, Yijun Hu, Zongyuan Ge, Honghua Yu and Mingguang He
    Citation: Alzheimer's Research & Therapy 2023 15:7
  20. High continuity of care (COC) is associated with better clinical outcomes among older adults. The impact of amyloid-β PET scan on COC among adults with mild cognitive impairment (MCI) or dementia of uncertain ...

    Authors: Emily C. O’Brien, Cassie B. Ford, Corinna Sorenson, Eric Jutkowitz, Megan Shepherd-Banigan and Courtney Van Houtven
    Citation: Alzheimer's Research & Therapy 2023 15:6
  21. Dementia and psychotropic medications are discussed as risk factors for severe/lethal outcome of the coronavirus disease 2019 (COVID-19). We aimed to explore the associations between the presence of dementia a...

    Authors: Juraj Secnik, Maria Eriksdotter, Hong Xu, Martin Annetorp, Aleksander Rytarowski, Kristina Johnell, Sara Hägg and Dorota Religa
    Citation: Alzheimer's Research & Therapy 2023 15:5
  22. Behavioral variant frontotemporal dementia (bvFTD) is predominantly considered a dysfunction in cortico-cortical transmission, with limited direct investigation of cortical-subcortical transmission. Thus, we a...

    Authors: Li Liu, Min Chu, Binbin Nie, Deming Jiang, Kexin Xie, Yue Cui, Lin Liu, Yu Kong, Zhongyun Chen, Haitian Nan, Pedro Rosa-Neto and Liyong Wu
    Citation: Alzheimer's Research & Therapy 2023 15:3
  23. Accessible and cost-effective diagnostic tools are urgently needed to accurately quantify blood biomarkers to support early diagnosis of Alzheimer’s disease (AD). In this study, we investigated the ability of ...

    Authors: María Pascual-Lucas, José Antonio Allué, Leticia Sarasa, Noelia Fandos, Sergio Castillo, Jose Terencio, Manuel Sarasa, Juan Pablo Tartari, Ángela Sanabria, Lluís Tárraga, Agustín Ruíz, Marta Marquié, Sang Won Seo, Hyemin Jang and Mercè Boada
    Citation: Alzheimer's Research & Therapy 2023 15:2
  24. Patterns of cognitive impairment in former American football players are uncertain because objective neuropsychological data are lacking. This study characterized the neuropsychological test performance of for...

    Authors: Michael L. Alosco, William B. Barr, Sarah J. Banks, Jennifer V. Wethe, Justin B. Miller, Surya Vamsi Pulukuri, Julia Culhane, Yorghos Tripodis, Charles H. Adler, Laura J. Balcer, Charles Bernick, Megan L. Mariani, Robert C. Cantu, David W. Dodick, Michael D. McClean, Rhoda Au…
    Citation: Alzheimer's Research & Therapy 2023 15:1
  25. Non-modifiable risk factors of Alzheimer’s disease (AD) have lifelong effects on cortical integrity that could be mitigated if identified at early stages. However, it remains unknown whether cortical microstru...

    Authors: Marina Fernandez-Alvarez, Mercedes Atienza and Jose L. Cantero
    Citation: Alzheimer's Research & Therapy 2022 14:202
  26. Alpha-synuclein (α-syn) is considered the main pathophysiological protein component of Lewy bodies in synucleinopathies. α-Syn is an intrinsically disordered protein (IDP), and several types of structural conf...

    Authors: Kyu Hwan Shim, Min Ju Kang, Young Chul Youn, Seong Soo A. An and SangYun Kim
    Citation: Alzheimer's Research & Therapy 2022 14:201
  27. Increasing evidence has supported a link between obstructive sleep apnea (OSA) and cognition, and blood-brain barrier (BBB) dysfunction which can be reflected by paroxysmal slow wave events (PSWEs) may be a po...

    Authors: Mengfan Li, Zhuoran Sun, Hairong Sun, Guochen Zhao, Bing Leng, Tengqun Shen, Song Xue, Huimin Hou, Zhenguang Li and Jinbiao Zhang
    Citation: Alzheimer's Research & Therapy 2022 14:200
  28. Alzheimer’s disease (AD) and frontotemporal dementia (FTD) show network dysfunctions linked with cognitive deficits. Within this framework, network abnormalities between AD and FTD show both convergent and div...

    Authors: Lorenzo Pini, Siemon C de Lange, Francesca Benedetta Pizzini, Ilaria Boscolo Galazzo, Rosa Manenti, Maria Cotelli, Samantha Galluzzi, Maria Sofia Cotelli, Maurizio Corbetta, Martijn P van den Heuvel and Michela Pievani
    Citation: Alzheimer's Research & Therapy 2022 14:199
  29. Efavirenz is an anti-HIV drug, and cytochrome P450 46A1 (CYP46A1) is a CNS-specific enzyme that metabolizes cholesterol to 24-hydroxycholesterol (24HC). We have previously shown that allosteric CYP46A1 activat...

    Authors: Alan J. Lerner, Steven E. Arnold, Erin Maxfield, Aaron Koenig, Maria E. Toth, Brooke Fortin, Natalia Mast, Bianca A. Trombetta, John Denker, Andrew A. Pieper, Curtis Tatsuoka, Sangeetha Raghupathy and Irina A. Pikuleva
    Citation: Alzheimer's Research & Therapy 2022 14:198
  30. The identification of biomarkers for early detection of Alzheimer’s disease (AD) is critical to the development of therapies and interventions targeted at symptom management and tracking the pathophysiology of...

    Authors: Michael D. Oliver, Cassandra Morrison, Farooq Kamal, Jillian Graham and Mahsa Dadar
    Citation: Alzheimer's Research & Therapy 2022 14:197
  31. In Alzheimer’s disease (AD), amyloid-β 1–42 (Aβ42) neurotoxicity stems mostly from its soluble oligomeric aggregates. Studies of such aggregates have been hampered by the lack of oligomer-specific research too...

    Authors: Anders Sandberg, Ernesto Berenjeno-Correa, Rosa Crespo Rodriguez, Michael Axenhus, Sophia Schedin Weiss, Kevin Batenburg, Jeroen J. M. Hoozemans, Lars O. Tjernberg and Wiep Scheper
    Citation: Alzheimer's Research & Therapy 2022 14:196
  32. The extracellular buildup of amyloid beta (Aβ) plaques in the brain is a hallmark of Alzheimer’s disease (AD). Detection of Aβ pathology is essential for AD diagnosis and for identifying and recruiting researc...

    Authors: Abby L. Brand, Paige E. Lawler, James G. Bollinger, Yan Li, Suzanne E. Schindler, Melody Li, Samir Lopez, Vitaliy Ovod, Akinori Nakamura, Leslie M. Shaw, Henrik Zetterberg, Oskar Hansson and Randall J. Bateman
    Citation: Alzheimer's Research & Therapy 2022 14:195
  33. Alzheimer’s disease (AD) shares risk factors with cardiovascular disease (CVD) and dysregulated cholesterol metabolism is a mechanism common to both diseases. Cholesterol efflux capacity (CEC) is an ex vivo me...

    Authors: Yi-An Ko, Jeffrey T. Billheimer, Nicholas N. Lyssenko, Alexandra Kueider-Paisley, David A. Wolk, Steven E. Arnold, Yuk Yee Leung, Leslie M. Shaw, John Q. Trojanowski, Rima F. Kaddurah-Daouk, Mitchel A. Kling and Daniel J. Rader
    Citation: Alzheimer's Research & Therapy 2022 14:194
  34. Hypertension has been associated with Alzheimer’s disease (AD) dementia as well as vascular dementia. However, the underlying neuropathological changes that link hypertension to AD remain poorly understood. In...

    Authors: Taewon Kim, Dahyun Yi, Min Soo Byun, Hyejin Ahn, Joon Hyung Jung, Nayeong Kong, Min Jung Kim, Gijung Jung, Jun-Young Lee, Yun-Sang Lee, Yu Kyeong Kim and Dong Young Lee
    Citation: Alzheimer's Research & Therapy 2022 14:193
  35. Cerebrospinal fluid (CSF) tau biomarkers are reliable diagnostic markers for Alzheimer’s disease (AD). However, their strong association with amyloid pathology may limit their reliability as specific markers o...

    Authors: Joel Simrén, Wagner S. Brum, Nicholas J. Ashton, Andrea L. Benedet, Thomas K. Karikari, Hlin Kvartsberg, Emma Sjons, Firoza Z. Lussier, Mira Chamoun, Jenna Stevenson, Robert Hopewell, Vanessa Pallen, Keqiang Ye, Tharick A. Pascoal, Henrik Zetterberg, Pedro Rosa-Neto…
    Citation: Alzheimer's Research & Therapy 2022 14:192
  36. Lecanemab, a humanized IgG1 monoclonal antibody that targets soluble aggregated Aβ species (protofibrils), has demonstrated robust brain fibrillar amyloid reduction and slowing of clinical decline in early AD....

    Authors: Eric McDade, Jeffrey L. Cummings, Shobha Dhadda, Chad J. Swanson, Larisa Reyderman, Michio Kanekiyo, Akihiko Koyama, Michael Irizarry, Lynn D. Kramer and Randall J. Bateman
    Citation: Alzheimer's Research & Therapy 2022 14:191
  37. Neuropsychiatric symptoms are important treatment targets in the management of dementia and can be present at very early clinical stages of neurodegenerative diseases. Increased cortisol has been reported in A...

    Authors: Sami Ouanes, Miriam Rabl, Christopher Clark, Clemens Kirschbaum and Julius Popp
    Citation: Alzheimer's Research & Therapy 2022 14:190
  38. Blood-based neurofilament light chain (NfL) is a promising biomarker of neurodegeneration across multiple neurodegenerative diseases. However, blood-based NfL is highly associated with renal function in older ...

    Authors: Rongxiang Tang, Matthew S. Panizzon, Jeremy A. Elman, Nathan A. Gillespie, Richard L. Hauger, Robert A. Rissman, Michael J. Lyons, Michael C. Neale, Chandra A. Reynolds, Carol E. Franz and William S. Kremen
    Citation: Alzheimer's Research & Therapy 2022 14:189
  39. Understanding the treatment needs of patients with dementia with Lewy bodies (DLB) is essential to develop treatment strategies. We examined the treatment needs of patients with DLB and their caregivers and th...

    Authors: Mamoru Hashimoto, Yuta Manabe, Takuhiro Yamaguchi, Shunji Toya and Manabu Ikeda
    Citation: Alzheimer's Research & Therapy 2022 14:188

    The Correction to this article has been published in Alzheimer's Research & Therapy 2023 15:4

  40. Granulovacuolar degeneration bodies (GVBs) are intracellular vesicular structures that commonly accompany pathological tau accumulations in neurons of patients with tauopathies. Recently, we developed the firs...

    Authors: Marta Jorge-Oliva, Jasper F. M. Smits, Vera I. Wiersma, Jeroen J. M. Hoozemans and Wiep Scheper
    Citation: Alzheimer's Research & Therapy 2022 14:187
  41. Alzheimer’s disease has become one of the most common neurodegenerative diseases worldwide, which seriously affects the health of the elderly. Early detection and intervention are the most effective prevention...

    Authors: Qin Yang, Xin Li, Xinyun Ding, Feiyang Xu and Zhenhua Ling
    Citation: Alzheimer's Research & Therapy 2022 14:186
  42. To investigate the characteristics and associations of MRI-visible perivascular spaces (PVS) with clinical progression and longitudinal cognitive decline across the Alzheimer’s disease spectrum.

    Authors: Ming-Liang Wang, Qiao-Qiao Zou, Zheng Sun, Xiao-Er Wei, Peng-Yang Li, Xue Wu and Yue-Hua Li
    Citation: Alzheimer's Research & Therapy 2022 14:185
  43. Growing evidence has showed an association between habitual glucosamine use and type 2 diabetes (T2D). However, the effect of habitual glucosamine use on risk of dementia remains poorly understood. Our study a...

    Authors: Chenjie Xu, Yabing Hou, Xuexian Fang, Hongxi Yang and Zhi Cao
    Citation: Alzheimer's Research & Therapy 2022 14:184
  44. Alzheimer’s disease (AD) is the most prevalent neurodegenerative disease worldwide and remains without effective cure. Increasing evidence is supporting the mitochondrial cascade hypothesis, proposing that los...

    Authors: Christina F. de Veij Mestdagh, Frank Koopmans, Jonathan C. Breiter, Jaap A. Timmerman, Pieter C. Vogelaar, Guido Krenning, Huibert D. Mansvelder, August B. Smit, Robert H. Henning and Ronald E. van Kesteren
    Citation: Alzheimer's Research & Therapy 2022 14:183
  45. Lecanemab (BAN2401) is a humanized IgG1 monoclonal antibody that preferentially targets soluble aggregated Aβ species (protofibrils) with activity at insoluble fibrils and slowed clinical decline in an 18-mont...

    Authors: Shobha Dhadda, Michio Kanekiyo, David Li, Chad J. Swanson, Michael Irizarry, Scott Berry, Lynn D. Kramer and Donald A. Berry
    Citation: Alzheimer's Research & Therapy 2022 14:182